Ching-Wen Hou

Ching-Wen Hou

Auto-generated profile, based on publicly available information

Ching-Wen Hou

Biodesign Center for Personalized Diagnostics, Arizona State University, AZ, 85287, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
CHChing-Wen Hou
Ching-Wen Hou
SWStacy Williams
Stacy Williams
KTKylee Taylor
Kylee Taylor
VBVeronica Boyle
Veronica Boyle
BBBradley Bobbett
Bradley Bobbett
Vel MuruganVel Murugan
Vel Murugan
Objective This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. Design Prospective cohort study. Settings A large public university. Participants This study took volunteers over 5 days and recruited 1064 adult participants. Primary outcome measures Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. Results The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels. Conclusion Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates or reverting to online classes. It could help us to have clear guidance to act at the first sign of the next surge as well, especially since there is a surge of COVID-19 subvariant infections.

3 January 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
CHChing-Wen Hou
Ching-Wen Hou
SWStacy Williams
Stacy Williams
GTGuillermo Trivino-Soto
Guillermo Trivino-Soto
VBVeronica Boyle
Veronica Boyle
DRDavid Rainford
David Rainford
Vel MuruganVel Murugan
Vel Murugan
Omicron is the comparatively most transmissible and contagious variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). We conducted a seroprevalence study from March 1–3, 2022, to investigate the seroprevalence of SARS-CoV-2 antibodies among individuals aged 18 years and older after the Omicron outbreak. The seroprevalence of anti-receptor binding domain (RBD) antibodies was found to be 96.3% (95% CI 95.2–97.2%) compared to 88.2% (95% CI 86.1–90%) in our previous serosurvey. For anti-nucleocapsid (NC) antibodies, the seroprevalence was 39.1% (95% CI 36.6–41.7%) compared to 19.7% (95% CI 17.5–22.2%) earlier. Individuals that experienced breakthrough infections exhibited the highest levels of anti-RBD antibodies. Additionally, saliva samples showed promise as a potential diagnostic biofluid for measuring antibody levels, as they exhibited a strong agreement with the data obtained from serum samples. The near doubling of anti-NC reactivity, a proxy for history of infection, reflects the contagiousness of the omicron variant, but may also have been influenced by a more relaxed approach to precautions in the spring of 2022. Serosurveys repeated at regular intervals monitor the trend of infections in the community, delineate the geographical spread of the infection, and may guide containment measures in communities, and prompt response to future outbreaks.

7 May 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
SMSEYEDSINA MIRJALILI
SEYEDSINA MIRJALILI
AIAshif Ikbal
Ashif Ikbal
CHChing-Wen Hou
Ching-Wen Hou
MMMaziyar Kalateh Mohammadi
Maziyar Kalateh Mohammadi
YCYeji Choi
Yeji Choi
CWChao Wang
Chao Wang

1 February 2025 in Cancer Biomarkers
Verified
Journal Article
Open access
CHChing-Wen Hou
Ching-Wen Hou
PKPankaj Kumar
Pankaj Kumar
SWStacy Williams
Stacy Williams
MZMeilin Zhu
Meilin Zhu
UOUwa Obahiagbon
Uwa Obahiagbon
KAKaren S. Anderson
Karen S. Anderson
Background: Among head and neck squamous cell carcinomas (HNSCCs), the incidence of oropharyngeal cancer (OPC) has been increasing in recent decades. Human papillomavirus (HPV) type 16 is associated with the majority of OPC. Circulating antibodies (Abs) to multiple HPV16 early antigens, including E2, E6, and E7, have been detected in patient sera, and are strongly associated with risk for OPC. However, HPV serology currently requires laboratory-based tests that are difficult to implement for large-scale cancer screening. Objective: The goal of this study was to develop and validate a point-of-care assay for rapid detection of circulating IgG to HPV16 early antigens. Methods: We measured Abs to HPV16 E2, E6, and E7 proteins using a lateral flow assay (LFA) in sera from 119 newly diagnosed OPC cases, 41 partners, and 81 healthy volunteers. The 119 patients with HPV-OPC were classified as HPV-positive based on in situ hybridization (ISH) or institutional p16 immunohistochemistry. The sensitivity and specificity of the LFA were determined by comparing to clinical diagnosis. Results: The specificity for each individual HPV16 E2, E6, and E7 antibodies was 95.1% (77/81), 96.3% (78/81), and 98.7% (80/81), respectively. The sensitivities of the individual HPV16 antibodies were as follows: E2, 47.9% (57/119), E6, 31.9% (38/119), and E7, 57.1% (68/119). The 3-biomarker panel (at least one positive for E2, E6, and E7 Abs) demonstrated a sensitivity of 76.5% (91/119) and a specificity of 92.6% (75/81). Conclusions: We developed a multiplexed lateral flow assay for the rapid detection of serologic responses to HPV16. Further research is required to determine the utility of these tests for HPV + HNSCC cancer screening, as higher specificity, and an assessment of the benefits of positive test results have yet to be evaluated in this context.

12 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
CHChing-Wen Hou
Ching-Wen Hou
SWStacy Williams
Stacy Williams
VBVeronica Boyle
Veronica Boyle
ARAlexa J. Roeder
Alexa J. Roeder
BBBradley Bobbett
Bradley Bobbett
Vel MuruganVel Murugan
Vel Murugan
Background/Objectives: Since the World Health Organization declared COVID-19 a pandemic in March 2020, the virus has caused multiple waves of infection globally. Arizona State University (ASU), the largest four-year university in the United States, offers a uniquely diverse setting for assessing immunity within a large community. This study aimed to test our hypothesis that an increased number of exposures to SARS-CoV-2 RBD through vaccination/boosters/infection will increase SARS-CoV-2 antibody seroprevalence by increasing the longevity of anti-RBD and anti-RBD-neutralizing antibodies. Methods: A serosurvey was conducted at ASU from 30 January to 3 February 2023. Participants completed questionnaires about demographics, respiratory infection history, symptoms, and COVID-19 vaccination status. Blood samples were analyzed for anti-receptor binding domain (RBD) IgG and anti-nucleocapsid (NC) antibodies, offering a comprehensive view of immunity from both natural infection and vaccination. Results: The seroprevalence of anti-RBD IgG antibodies was 96.2% (95% CI: 94.8–97.2%), and 64.9% (95% CI: 61.9–67.8%) of participants had anti-NC antibodies. Anti-RBD IgG levels correlated strongly with neutralizing antibody levels, and participants who received more vaccine doses showed higher levels of both anti-RBD IgG and neutralizing antibodies. Increasing the number of exposures through vaccination and/or infection resulted in higher and long-lasting antibodies. Conclusions: The high levels of anti-RBD antibodies observed reflect substantial vaccine uptake within this population. Ongoing vaccination efforts, especially as new variants emerge, are essential to maintaining protective antibody levels. These findings underscore the importance of sustained public health initiatives to support broad-based immunity and protection.

29 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CHChing-Wen Hou
Ching-Wen Hou
SWStacy Williams
Stacy Williams
GTGuillermo Trivino-Soto
Guillermo Trivino-Soto
VBVeronica Boyle
Veronica Boyle
DRDavid Rainford
David Rainford
Vel MuruganVel Murugan
Vel Murugan
Objective This study aimed to investigate the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibodies among individuals aged 18 years and older Design Prospective cohort study. Settings Population-based study was conducted within the Arizona State University (ASU) community. Participants The study recruited 1,397 adult participants that volunteered over a period of three days (March 1-March 3 of 2022). Primary outcome measures Seroprevalence was conducted in the community to assess the presence of SARS-CoV-2-specific antibodies resulting from previous exposure to SARS-CoV-2 and/or vaccination. Results The seroprevalence of anti-receptor binding domain (RBD) antibodies was found to be 96.3% using a semi-quantitative chemiluminescent immunoassay and 98% using an electrochemiluminescent immunoassay. For anti-nucleocapsid (NC) antibodies, the seroprevalence was 39.1% by an ELISA assay and 41.4% by an electrochemiluminescent immunoassay. Individuals that experienced breakthrough infections exhibited the highest levels of anti-RBD antibodies. Additionally, saliva samples showed promise as a potential diagnostic biofluid for measuring antibody levels, as they exhibited a strong correlation with the data obtained from serum samples. Conclusion Accurate estimation of population-based serosurveillance for SARS-CoV- 2 will monitor the trend of infection in the community and delineate the geographical spread of the infection. Cumulative incidence of SARS-CoV-2 infection during and after outbreaks is crucial for informing the development of effective risk mitigation protocols within the community. Protocols may include measures such as encouraging booster shots, extending mask mandates, or transitioning to online classes. Serosurveys repeated at regular intervals can also guide containment measures in communities and prompt response to future outbreaks. Strengths and limitations of this study We simultaneously investigated active infection and seroprevalence for the university population. Our study was strengthened by having the participants’ self-report data independently validated with diagnostic tests. Saliva samples could be a potential diagnostic biofluid for measuring antibody levels. Our study was performed within the university setting therefore it only reflects the COVID-19 situation within that community. The number of breakthrough infections and the longitudinal samples were small, thus requiring confirmation.